Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
bone mineral density
Advertisement
Entera Bio Advances EB613 Toward Phase 3 Development Following FDA Alignment
TEL AVIV, August 7, 2026 Entera Bio reported its second quarter 2026 financial results and business updates, highlighting regulatory...
Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Ultragenyx Reports Phase 3 Setrusumab Results in OI
NOVATO, Calif., December 29, 2025 — Ultragenyx Pharmaceutical announced results from its Phase 3 Orbit and Cosmic clinical trials...
Advertisement
